• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fractyl activates 10th clinical site in diabetes reversal tech trial

September 1, 2021 By Sean Whooley

Fractyl HealthFractyl Health announced today that it activated the 10th clinical site in its pivotal REVITA-T2Di trial in the U.S. and Europe.

Lexington, Mass.-based Fractyl’s trial is enrolling patients with type 2 diabetes who are currently on insulin therapy at sites in New Jersey, Louisiana, Texas, Massachusetts and New York to add to the initial U.S. site at Indiana University Health. Additionally, enrollment is ongoing in Belgium, Italy and the Netherlands.

REVITA-T2Di — a prospective, randomized, double-blind, sham-controlled study expected to enroll more than 300 patients at up to 35 sites in the U.S. and Europe —  will evaluate the efficacy of Fractyl’s Revita DMR procedure. The company set a primary endpoint of the percentage of patients who are able to achieve target glycemic control (HbA1c less than or equal to 7%) without the need for insulin at 24 weeks, comparing Revita DMR to the sham arm, according to a news release.

In April, Fractyl garnered FDA breakthrough device designation for its Revita DMR procedure designed to resurface the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes. Through the procedure, the company aims to minimize or eliminate the need for type 2 diabetes patients to receive insulin treatment.

READ: “How Fractyl Labs is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections” — an interview with co-founder & CEO Harith Rajagopalan.

Principal investigator Dr. Vivan Fonseca, who serves as assistant dean for clinical research and Tullis-Tulane alumni chair in diabetes at Tulane University School of Medicine, said in the release that the team is excited to participate in a study of a “potentially important addition to the therapeutic armamentarium of physicians treating diabetes.”

“This exciting clinical trial is the first to evaluate the ability of a procedural therapy to reduce or eliminate the need for insulin in patients with advanced type 2 diabetes, a critical therapeutic need. We are grateful to the prestigious medical centers who have partnered with us to carry out this study,” Fractyl CMO Dr. Juan Carlos Lopez-Talavera said.  “As we continue to enroll and treat patients at numerous sites in the U.S. and Europe, we remain focused on strong clinical execution with a sense of urgency for the patients we seek to serve.”

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: Fractyl Health, fractyllaboratories

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS